IDEXX Laboratories Inc. (NASDAQ:IDXX) reported better-than-expected fourth-quarter financial results and issued a fiscal 2026 forecast on Monday.
The animal health company reported fourth-quarter 2025 earnings of $3.08 per share, up 18% year over year, beating the consensus of $2.94. Comparable earnings were $2.92 per share. The company reported sales of $1.091 billion, beating the consensus of $1.073 billion, up 14% on a reported and 12% on an organic basis.
“We enter 2026 with an exciting innovation pipeline, expanding instrument and software installed bases, and strong momentum across our global business,” said Jay Mazelsky, President and CEO, in a press release on Monday.
IDEXX Laboratories expects fiscal 2026 earnings of $14.29-$14.80 per share compared to the consensus of $14.39.
The pet healthcare company forecasts 2026 annual sales of $4.632 billion-$4.720 billion compared to the consensus of $4.658 billion, led by CAG Diagnostics recurring revenue growth of 8.6% – 10.6% as reported and 8.0% – 10.0% on an organic basis.
IDEXX Laboratories shares gained 1.7% to trade at $650.54 on Tuesday.
These analysts made changes to their price targets on IDEXX Laboratories following earnings announcement.
- BTIG analyst Mark Massaro maintained IDEXX Laboratories with a Buy and lowered the price target from $830 to $800.
- UBS analyst Andrea Alfonso maintained the stock with a Neutral and lowered the price target from $750 to $730.
Considering buying IDXX stock? Here’s what analysts think:
Photo via Shutterstock
Recent Comments